Anemia Features

Expert Q&A Renal Stenting and the CORAL Study: Interview with Lance Dworkin, MD

Renal Stenting and the CORAL Study: Interview with Lance Dworkin, MD

CORAL study chair Lance Dworkin, MD, discusses the controversial finding with Renal & Urology News.

Departments Guidelines and the Older Patient with CKD

Guidelines and the Older Patient with CKD

Geriatric patients with CKD are at high risk for morbidity and mortality from the potential side effects of treatments.

Latest Anemia News

Body Fat May Improve Anemia Drug Response

Body Fat May Improve Anemia Drug Response

Hemodialysis patients with a higher percentage of fat tissue respond better to erythropoiesis-stimulating agents.

Pre-Surgery Anemia Ups CKD Patients' Risks

Pre-Surgery Anemia Ups CKD Patients' Risks

Low hemoglobin levels increase the risk of death, sepsis, and cerebrovascular accidents following cardiac surgery.

ESA Use in Dialysis Patients May Increase Their Cancer Risk

ESA Use in Dialysis Patients May Increase Their Cancer Risk

Doses higher than 70 μg per week were associated with a 77% greater risk of cancer compared with non-use of the agents.

Ascorbic Acid Found to Reduce Darbepoetin Requirement

Ascorbic Acid Found to Reduce Darbepoetin Requirement

It also was associated with high hemoglobin levels and reduced levels of C-reactive protein.

Value of ESAs in Avoiding Transfusion Questionable

Value of ESAs in Avoiding Transfusion Questionable

In 3 trials, the annual cost for preventing 1 patient from being transfused varied from $61,188 to $317,988.

Anemia Management Changing in Peritoneal Dialysis Patients

Anemia Management Changing in Peritoneal Dialysis Patients

Study reveals a decline in the use of erythropoiesis-stimulating agents and an increase in the use of iron.

High Phosphorus Ups Anemia Risk in the Non-CKD Population

High Phosphorus Ups Anemia Risk in the Non-CKD Population

Each 0.5 mg/dL increment in phosphorus was associated with a 7% increased risk of anemia.

Inappropriate ESA Use Reduced by Pharmacy Protocol

Inappropriate ESA Use Reduced by Pharmacy Protocol

Ordering process cut the number of epoetin alfa doses by 71% and medication costs by 69%.

Safety Profiles of IV Iron Products Compared

Safety Profiles of IV Iron Products Compared

In a head-to-head comparison, researchers observed a higher rate of adverse events with iron dextran than iron sucrose or ferric gluconate.

Phosphate Binder May Eliminate Need for IV Iron

Phosphate Binder May Eliminate Need for IV Iron

Iron absorbed from oral ferric citrate boosted iron stores and sustained hemoglobin levels.

CMV in Kidney Disease Linked with Anemia

CMV in Kidney Disease Linked with Anemia

Patients with higher levels of anti-CMV antibodies have lower number of red blood cells.

ESA Resistance Found To Increase Mortality

Greater resistance to ESA is associated with an increased risk of death among patients on chronic HD.

MI-Acquired Anemia Rates Vary by Hospital

MI-Acquired Anemia Rates Vary by Hospital

Considerable variation in incidence of HAA across hospitals; teaching status and region linked to risk.

Ribavirin May Treat HEV Infection in Transplant Recipients

Ribavirin May Treat HEV Infection in Transplant Recipients

Serum hepatitis E virus levels were undetectable in 78% of patients at least 6 months after stopping treatment.

IV Iron Drugs Demonstrate Similar Efficacy, AE Rates

Ferumoxytol and iron sucrose have comparable safety in the treatment of anemia in patients with CKD.